Economy

India’s daily Covid cases in downward spiral, infections at 74-day low of 70,421 on Monday

Our Bureau New Delhi | Updated on June 14, 2021

The death toll in the country climbed to 3,74,305

The Covid-19 cases seem to be finally ebbing, with the country reporting 74-day lowest Covid 19 infections on Monday at 70,421 and active caseload below 10-lakh mark after 66 days. On Sunday, India registered 80,834 infections, the lowest in the last 72-days with 3,303 deaths in a single day.

However, mortalities due to Coronavirus infection continue to be a cause of worry as Covid deaths hover near 4,000-level at 3,921 till 8 am on Monday, as per the Health Ministry data. Cumulatively, India reported 2,95,10,410 coronavirus cases of which active caseload is at 9,73,158, total recovery at 2,81,62,947 and the death toll stood at 3,74,305 till 8 AM.

Meanwhile, more than 1.19 lakh patients at 1,19,501 recovered during the last 24 hours till 8 am. Recoveries continue to outnumber the daily new cases for the 32nd consecutive day, and the recovery rate has further expanded to 95.43 per cent.

Besides this, the weekly positivity rate has dropped to 4.54 per cent, and the daily positivity rate is at 4.72 per cent, less than 10 per cent for 21 consecutive days.

In addition, India administered 25,48,49,301 vaccine doses in the previous day, with 14,99,771 shots given in the last 24 hours till 7 am. Also, the number of Covid tests done on Sunday stood at 14,92,152.

Liposomal Amphotericin B drug allocation

Apart from this, for the Covid treatment, the Government allocated an additional 1,06,300 vials of the drug Liposomal Amphotericin B, to all the States/UTs and Central Institutions on Monday, the Chemicals and Fertilizers Minister Sadanada Gowda tweeted Monday. In yet another tweet, he said a total of 53,000 vials of Conventional Amphotericin B have also been allocated to all the States/UTs & Central Institutions.

Also read: Public sector banks support for Covid-19 health infra gathers pace

 

Published on June 14, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor